foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Please, do no hesitate to contact me in case you have any further question, need further input or any problem arises during the revision process.
Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS:
In this manuscript the authors show that expression of the Myocardin gene is enhanced in differentiated vascular smooth cells (VSMCs) and accordingly expression of the MRFT-A gene is reduced. However, in activated, de-differentiated and proliferative VSMCs the expression pattern of the aforementioned genes is reversed. Additionally, MRTF-A expression is enhanced in different models which induce vasculature smooth muscle lesions, such as femoral artery lesions, carotid artery ligation and vascular atherosclerosis in the ApoE-/-mouse model. In these models, the observed result is the activation of vascular smooth muscle cells which are induced to dedifferentiate and proliferate. As a consequence, MRFT-A expression is enhanced along with the SRF responsive molecular markers such as vinculin, MMP-9 and integrin-. In contrast Myocardin expression is reduced. Additionally, MRTF-A Knock down in VSMCs results in reduction of the proliferative and migratory potential. As with the in vitro model, MRTF-A -/-mice show reduced VSMCs proliferation and thus attenuation in vessel repair after injury. Similarly, a MRTF-A-/-, ApoE-/-double knock out model shows attenuated arterial atherosclerotic lesions after high fat diet.
Molecularly, mir-1 is shown to be expressed in VSMCs and is down-regulated after arterial injury and in ApoE-/-aortic VSMCs; following a similar trend observed in Myocardin expression. Additionally, the MRTF-A 3'UTR contains an evolutionary conserved mir-1 recognition site which is shown to be sufficient to down-regulate MRTF-A expression. Moreover, CCG1423 has been recently found to be an MRTF-A inhibitor. Treating VSMCs with CCG1423 also reduces proliferative and migratory potential a result also seen when MRTF-A is knocked-down. However, CCG1423 does not affect MRTF-A expression, but affects its nuclear translocation.
The authors conclude that MRTF-A is essential for the activation and de-differentiation of VSMCs for arterial repair after injury and that MRTF-A presents itself as a target for a therapeutic model.
Comments: 1.
Picture used in Fig. 3G . is identical to the one used in Fig. 3B . It shown that MRTF-A is expressed within lesion sites in the ApoE-/-model. It is suggested that vascular remodeling after injury is mediated by MRTF-A. Also, showing of the results obtained (even if they are negative) in wild type would reinforce the results obtained in the Mkl1-/-, ApoE-/-double knockout.
2.
The hypothesis that mir-1 regulates MRTF-A expression is not strongly connected to the main objective of the study. The authors established that mir-1 is co-expressed with and due to Myocardin and therefore MRTF-A is downregulated. a.
The authors initially infer that MRTF-A expression is regulated by the 3'UTR since the results obtained with the promoter region were negative. In this sense; is the MRTF-A promoter already defined and characterized?. As an example, Myocardin promoter has been defined as a 2Kb fragment upstream of the translational initiation site. Moreover, a Myocardin enhancer has been found to be located between 20Kb-30Kb upstream of the translation initiation site. Both fragments contain several transcription factor binding sites and Myocardin expression is regulated accordingly. In the MRTF-A case, the authors only use an ~1Kb fragment, which might not be sufficient to recapitulate MRTF-A expression. Moreover, the authors use MRTF-A and Myocardin to elicit a response in the Luciferase reporter assay. However, there is no explanation whether the ~1Kb fragment contains an SRF response element or not. The negative result might be misleading. Also, the authors note that a mutation at -184nt enhances MRTF-A activity, thus, one might ask, what region or which response element this mutation is modifying? b.
Mir-1 expression levels are shown to be extremely low in femoral artery and aorta (~50 times lower or more than those found in heart and skeletal muscle). Although, over-expression and knock-down experiments suggest that mir-1 in fact regulates MRTF-A expression, the results might not translate to physiological levels. Moreover, all mir-1 experimentation is performed in vitro. It would be exceptional if injection of anti-mir-1 results in the same phenotype in vivo as seen with the CCG14238 inhibitor. c.
The authors suggest that there is a feedback loop mechanism in which Myocardin regulated mir-1 expression which in turn regulates MRTF-A expression. MRTF-A knock down results in impaired remodeling due to reduction of proliferation and migration ability. Does Myocardin knock down have a similar effect?.
3.
The newly discovered MRTF-A inhibitor CCG14328 has been found to regulate MRTF-A function by inhibiting MRTF-A translocation the nucleus (similar to SARS activity on MRTF-A), thus inhibiting its activity. However, it also inhibits STARS activity as shown in the 3xCArG-Luciferase reporter assay. Might it be that the results obtained are a secondary effect mediated primarily by SARS?.
Referee #2:
Minami et al., analyzed the functional role of the myocardin-related factor MRTF-A during neointima formation. The authors report that MRTF-A promotes neointima formation and that genetic and pharmacological inhibition can prevent this process in mice. The authors show that vascular damage causes upregulation of MRTF-A in VSMCs and downregulation of Myocardin. MRTF-A -/-mice were somehow protected from neointima formation after wire injury and had less atherosclerotic plaques in the ApoE-/-model. A chemical inhibitor of RhoA-MRTF-A was efficient in the wire injury model implicating clinical relevance of this study. On the cellular level, MRTF-A regulates the SRF target genes vinculin, b1-integrin, cell migration and proliferation. This is not entirely new but fits to the in vivo data sets. The authors went on to search for a factor that regulates the reciprocal expression of Myocardin and MRTF-A. It was known before that Myocardin induces the miR-1 cluster. The authors describe a functional miR-1 binding site in the 3'UTR of MRTF-A and a potential regulatory loop. The data is strengthened by expression analyses in ApoE-/-mice or in neointima tissues after vascular damage. The manuscript is well written, succinct; the data are present in a clear manner.
Major points:
1) The manuscript would be improved if the authors would analyze the CCG-1423 compound in the ApoE-/-model to see if it also affects plaque formation or plaque size.
2) Further research is needed to test how MRTF-A loss affects fibrosis and myofibroblasts (Circ Res. 2010; 107(2):294-304.) in the vessel media.
3) The role of MRTF-A on VSMCS apoptosis needs to be evaluated to better determine the mechanism for the reduced neointima size.
Minor: 1) the CCG-1423 inhibitor should be described more carefully. It should be clearly stated that it is not completely specific for MRTF-A. Responses to the reviewers To Referee #1:
We appreciate the favourable review and the opportunity to improve our manuscript. The reviewer also raised several points, all of which we have addressed below.
Comments:
1. Picture used in Fig. 3G . is identical to the one used in Fig. 3B .
It shown that MRTF-A is expressed within lesion sites in the ApoE-/-model. It is suggested that vascular remodelling after injury is mediated by MRTF-A. Also, showing of the results obtained (even if they are negative) in wild type would reinforce the results obtained in the Mkl1-/-, ApoE-/-double knockout.
Thank you for your comment. We replaced the pictures with new ones showing identical results in the revised Fig. 3F . We also added a new picture showing MRTF-A staining in wild type aorta (negative staining) in the revised Fig. 3B . We describe the new data in the revised Figure legend on page 43. The nature of the MRTF-A promoter has not yet been defined extensively. We therefore initially examined the conservation of the 5'-flanking region (FR) of the MRTF-A gene among different species. We found that the 5'-FR is well conserved among different species only up to 1 kb from the transcription start site (e.g., between rodents and human). Therefore, we used the ~1 kbp 5'-FR of MRTF-A gene in this study. Within this region, we identified a possible SP-1-binding site 30 bp upstream of the transcription start site. However, as the reviewer points out, it is possible that a region more distant from transcription start site contributes to the regulation of MRTF-A gene expression in VSMCs. For that reason, we cloned the ~5.5 Kbp 5'-FR of the MRTF-A gene and then used this fragment to examine the mechanisms underlying the reciprocal expression of myocardin and MRTF-A. When we looked at the effects of myocardin on MRTF-A gene transcription, we failed to find any significant effects mediated via this region in VSMCs. This suggests myocardin does not directly or indirectly affect transcriptional activity mediated via this 5'-FR in VSMCs. These data are shown in the revised supplementary Fig. S5B , and are described the revised Results section on page 15, last 8 lines and page 16, line 1.
The hypothesis that mir-1 regulates MRTF-A expression is not strongly connected to the main objective of the study. The authors established that mir-1 is co-expressed with and due to Myocardin and therefore MRTF-A is down regulated. a. The authors initially infer that MRTF-A expression is regulated by the 3'UTR since the results obtained with the promoter region were negative. In this sense; is the MRTF-
We also mention the possibility that other mechanisms such as transcriptional regulation through sites located in the more distal 5'-FR or introns also contribute to the reciprocal regulation of myocardin and MRTF-A expression in the revised Discussion section on page 21, lines 1-4.
The reason we looked at the effects of myocardin and MRTF-A on MRTF-A promoter activity was to test the hypothesis that myocardin or MRTF-A itself affects MRTF-A gene transcription, either directly or indirectly, during the phenotypic modulation of VSMC, which could underlie the reciprocal expression of myocardin and MRTF-A. No conserved SRF response element (CArG) was found in the 1 kbp 5'-FR of MRTF-A gene. And because we failed to see any effects of myocardin on the transcriptional activity of the 5'-FR of MRTF-A gene in VSMCs, we next focused on the gene's 3'-UTR to further study the possible connection between myocardin and MRTF-A gene expression. To avoid any misunderstanding, we modified the sentences in the revised Results section on page 15, lines 10-17.
The precise role of the SNPs at -184 of the 5'-FR of MRTF-A gene is not known at present. No known transcription factor-targeting sequences overlap this region, though a potential Elk-1-binding site is located adjacent to the region. It appears, however, that a C-to-T change does not significantly affect the binding affinity to Elk1 based on the prediction from TFSEARCH. We preliminarily found that a protein that may contribute to the repression of MRTF-A gene binds to the minor allele. We are now trying to define this protein. We therefore think that this region contributes to modulating basal MRTF-A expression, but detailed characterization of the role played by this region is beyond the scope of this study.
b. Mir-1 expression levels are shown to be extremely low in femoral artery and aorta (~50 times lower or more than those found in heart and skeletal muscle). Although, over-expression and knockdown experiments suggest that mir-1 in fact regulates MRTF-A expression, the results might not translate to physiological levels. Moreover, all mir-1 experimentation is performed in vitro. It would be exceptional if injection of anti-mir-1 results in the same phenotype in vivo as seen with the CCG14238 inhibitor.
To address this comment, we introduced an anti-miR-1 LNA TM -enhanced microRNA inhibitor into wire-injured vessels. As shown in the revised supplementary Fig. S5E -G, administration of the antimiR-1 microRNA inhibitor increased MRTF-A expression and markedly enhanced the pathological response following wire injury to femoral arteries. This result supports our hypothesis that miR-1 in VSMCs contributes to the regulation of VSMC phenotypic modulation, even though the level of its expression in VSMCs is lower than in cardiac or skeletal muscle cells. We describe these results in the revised Results section on page 17, lines 11-15.
With respect to the relatively low levels of miR-1 expression in blood vessels, as compared to skeletal and cardiac muscle, there have been a number of reports showing the contribution of the down-regulation of miR-1 expression to tumorigenesis in cancers derived from other non-muscle tissues. These include colon cancer ( Oberg, et al. Plos one 6:e20465. 2011; Migliore, et al. Clin Cancer Res 18:737-47.2011 ), hepatocellular carcinoma (Datta, et al. Clin Cancer Res 68:5049-58.2008 ), lung cancer (Nasser, et al. J Biol Chem 283:33394-405. 2008 ), prostate cancer (Liu, et al. Oncogene. Epub ahead of print. 2012) and pharyngeal and esophageal squamous cell carcinoma (Nohata, et al. Oncotarget. 2: 49-51. 2011) , in all of which miR-1 expression appears to be lower than that in blood vessels. This evidence is consistent with our finding that the level of miR-1 expression in arteries (vascular smooth muscle cells) is sufficient to affect gene expression.
c. The authors suggest that there is a feedback loop mechanism in which Myocardin regulated mir-1 expression which in turn regulates MRTF-A expression. MRTF-A knock down results in impaired remodelling due to reduction of proliferation and migration ability. Does Myocardin knock down have a similar effect?.
In contrast to MRTF-A knockdown, myocardin knockdown in cultured VSMCs did not reduce cell proliferation or their migration capacity. We show these results in the revised supplementary Fig.  S4E , F and G. This result is consistent with our view that MRTF-A, not myocardin, is important for de-differentiated VSMCs to acquire capacities for proliferation and migration. In cultured VSMCs, a cellular model of de-differentiated VSMCs, levels of myocardin and miR-1 expression are very low, whereas MRTF-A expression is high. We therefore think that further reduction of myocardin would have a negligible effect the proliferation and migration capacity, whereas knocking down MRTF-A, which plays an important role in proliferation and migration as a mediator of Rho-dependent signalling in de-differentiated VSMCs, would significantly attenuate proliferation and migration elicited by extracellular stimuli in cultured VSMCs. We described these results in the revised Results section on page 15, lines 1-6. STARS is an actin binding protein that facilitates MRTF-A nuclear import in an actin dynamicsdependent manner (Kuwahara, et al. Mol Cell Biol 25: 3173-81. 2005 ). Overexpression of STARS alone can activate SRF by enhancing nuclear translocation of endogenously expressed MRTF-A. The experiment shown in Fig. 6B was performed using cultured RAVSMCs (rat aortic VSMCs), which strongly express endogenous MRTF-A (as shown in Figure 4B and C). CCG-1423 thus blocks STARS effects on SRF activity by inhibiting the activity of endogenous MRTF-A. Indeed, knocking down MRTF-A using siRNA in RAVSMCs abolished STARS activity leading to induction of SRF-mediated transcription. MRTF-A knockdown also prevented the inhibitory effects of CCG-1423 on the STARS activity. These results demonstrate that the effects of CCG-1423 are primarily mediated by MRTF-A inhibition (inhibitory effect of CCG-1423 on STARS activity is a secondary effect mediated by inhibiting endogenous MRTF-A activity). We show these results in the revised supplementary Fig. S6A and describe it in the revised Results section on page 18, lines 3-8.
The newly discovered MRTF-A inhibitor CCG1432 has been found to regulate MRTF-A function by inhibiting MRTF-A translocation the nucleus (similar to SARS activity on MRTF-
To Referee #2:
We appreciate the reviewer's instructive comments. The reviewer also raised several points, all of which we have addressed below.
Major points: 1) The manuscript would be improved if the authors would analyse the CCG-1423 compound in the ApoE-/-model to see if it also affects plaque formation or plaque size.
Following the suggestion, we administered CCG-1423 in ApoE KO mice and analysed the effect of CCG1423 on atherosclerotic lesions. As shown in the revised Fig. 6G and H, CCG-1423 significantly inhibited the development of atherosclerotic lesions in ApoE KO mice, which is consistent with our notion that MRTF-A plays a significant role in the development of pathological vascular remodelling. We describe this result in the revised Results section on page 19, lines 8-10. (Circ Res. 2010; 107(2):294-304.) in the vessel media.
2) Further research is needed to test how MRTF-A loss affects fibrosis and myofibroblasts
We address the effects of MRTF-A deletion on fibrosis in injured arteries. As shown in the revised supplementary Fig. S2E and F, % fibrotic areas in the media and neointima of injured arteries did not significantly differ between wild-type and MRTF-A knockout mice. Col1a1 and Col3a1 gene expression were also not significantly affected by MRTF-A knockout (revised supplementary Fig.  S2G ). We totally agree with the notion that MRTF-A plays an important role in myofibroblast activation and tissue fibrosis under some conditions, but the contribution of this pathway to the phenotypes seen in this vascular injury model seem not to be predominant. We describe these results in the revised Results section on page 11, line 1-4, and show the data in the revised supplementary Fig.S2E -G.
To further evaluate the contribution of MRTF-A expression in myofibroblasts to the results, we stained injured vessels with anti-smooth muscle myosin heavy chain (SM-MHC), a specific VSMC marker. As alpha smooth muscle actin (aSMA) can be expressed in both VSMC and myofibroblasts, we compared the staining by SM-MHC, aSMA and MRTF-A in the neointima regions of serial sections between the two genotypes. In neointimas of injured vessels in wild-type mice, most of the MRTF-A appears to be expressed in cells positive for both SM-MHC and aSMA, suggesting the major population of MRTF-A-expressing cells within injured vessels are of VSMC origin (mostly de-differentiated VSMCs) (revised Fig 1D) . In MRTF-A knockout mice, the numbers of neointimal cells positive for both SM-MHC and aSMA were diminished, as compared to that in wild-type vessels (revised Fig. 2D ), supporting our finding that MRTF-A is an important mediator of migration and proliferation by de-differentiated VSMCs following vascular injury. We describe these results in the revised Results section on page 8, last 3 lines and page10, lines 11-14.
3) The role of MRTF-A on VSMC apoptosis needs to be evaluated to better determine the mechanism for the reduced neointima size. To address this issue, we used TUNEL staining and cleaved caspse-3 staining to compared the numbers of apoptotic cells within injured vessels from wild-type and MRTF-A knockout mice. As shown in the revised supplementary Fig. S2A-D , the numbers of TUNEL-positive cells and cleaved caspse-3-positive cells did not significantly differ between the two genotypes, though they slightly tended to be higher in the MRTF-A knockout mice. We describe these results in the revised Results section on page 10, lines 17-19.
Minor: 1) the CCG-1423 inhibitor should be described more carefully. It should be clearly stated that it is not completely specific for MRTF-A.
Thank you for the comment. Following your suggestion, we modified the sentences describing CCG-1423 in the revised Results section on page 18, line 3-8.
